ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 945,00
1,42%
DAX
19 884,75
-0,57%
Brent Oil
72,655
0,37%
Bitcoin
96 865,04
-0,61%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amylyx Pharmaceuticals Inc (AMLX)

  7. Amylyx Pharmaceuticals Inc (AMLX) Actualités

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateHeureSourceTitreSymboleSociété
04/12/202413h30Business WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
27/11/202415h00Business WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202414h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202413h00Business WireAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202401h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/11/202415h00Business WireAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
17/10/202415h00Business WireAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
15/10/202415h00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/10/202421h06PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
28/08/202414h30Business WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
27/08/202400h49Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/08/202415h00Business WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202413h00Business WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/08/202415h00Business WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/08/202415h00Business WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202413h00Business WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/07/202422h01Business WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/06/202415h00Business WireAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202413h00Business WireAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/05/202415h00Business WireAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/202415h00Business WireAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/04/202415h00Business WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/04/202411h45PR Newswire (US)The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/04/202415h00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/04/202411h45PR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/04/202413h00Business WireAmylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and StrategyNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/04/202411h45PR Newswire (US)The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
29/03/202410h45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/03/202410h45PR Newswire (US)Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
EU
VIV
Vivendi
EU
HO
Thales
EU
PX4
SBF 120
NYSE
DIS
Walt Disney
EU
BEL20
Bel 20
NASDAQ
MSFT
Microsoft
COIN
ADAUSD
Cardano
EU
RI
Pernod Ricard
COIN
DOGEUSD
Dogecoin
EU
CS
Axa
NASDAQ
GOOGL
Alphabet
EU
BNP
BNP Paribas
USI
USTECH100
US Tech 100
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés